Shire plc — SEC financials & events

Financials

SEC XBRL · annual

	FY17	FY16	FY15	FY14	FY13	FY12
Revenue	$3.57B	$1.71B	$1.49B	$1.35B	$4.93B	$4.53B
Operating income	$2.46B	$962.9M	$1.42B	$1.70B	$1.73B	$1.05B
Net income	$375.0M	$419.0M	$410.4M	$230.4M	$665.1M	$745.4M
Total assets	$67.76B	$67.04B	$16.61B	$13.63B	$8.32B	$7.32B
Total liabilities	$31.58B	$38.09B	$6.78B	$4.97B	$2.96B	$3.51B
Equity	$36.18B	$28.95B	$9.83B	$8.66B	$5.37B	$3.81B
EPS (diluted)	$0.41	$0.71	$0.69	$0.39	$1.18	$1.31
Shares out.	904.7M	601.1M	599.2M	597.7M	562.6M	562.5M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2017

Operating margin: 68.7%
Net margin: 10.5%
Return on equity: 1.0%
Return on assets: 0.6%
Return on capital (ROCE): 4.1%
Liabilities / assets: 46.6%
Debt / equity: 0.87×
Book value / share: $39.99
Revenue growth (YoY): 109.0%
Net income growth (YoY): −10.5%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2017

Altman Z″ (distress): 1.90grey zone
Accruals / assets: −5.7%clean
Beneish M-Score: -1.90normal
Piotroski F-Score: 6/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score

67

/ 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

● 1 warning● 5 good

Altman Z″ in the grey zone
Operating margin is positive
Revenue is growing year-over-year
Conservative leverage (liabilities < 50% of assets)
Positive operating cash flow
Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

FDA-approved drugs

openFDA · most recent

ELAPRASEJul 24, 2006
SUPPRELINDec 24, 1991
ETHMOZINEJun 19, 1990
ANOQUANOct 1, 1986
TOPICYCLINESep 21, 1977
DEXTROSTATMay 29, 1975
DOPARJun 4, 1970
URACIL MUSTARDSep 13, 1962

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

Insider transactions

SEC Form 4 · most recent

1 acquisitions0 disposalsnet +183,619 shares · last 1

Insider	Date	Type	Shares	Price
Shire Human Genetic Therapies, Inc.10% owner	Jul 2, 2018	J	183,619	$0.00

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

SC 13GFeb 15, 2019
15-15DFORM 15-15DFeb 7, 2019
15-15DFORM 15-15DFeb 7, 2019
15-12BFORM 15Feb 7, 2019
EFFECTFeb 6, 2019
POS AMFORM POS AMFeb 4, 2019
S-8 POSFORM S-8 POSFeb 4, 2019
S-8 POSFORM S-8 POSFeb 4, 2019
S-8 POSFORM S-8 POSFeb 4, 2019
S-8 POSFORM S-8 POSFeb 4, 2019
POSASRFORM POSASRFeb 4, 2019
25FORM 25Jan 22, 2019
SC 13G/AJan 11, 2019
8-KFORM 8-KJan 11, 2019
SC 13G/AJan 10, 2019